Termine Provectus Biopharmaceuticals, Inc. OTC Bulletin Board

Aktien

A1XCTC

US74373P1084

PVCT

Schlusskurs OTC Bulletin Board % 5 Tage % 1. Jan.
- USD -.--% Intraday Chart für Provectus Biopharmaceuticals, Inc. -.--% -.--%

Terminchart Provectus Biopharmaceuticals, Inc.

5d7.olvPJIq6ewy6O4qjGyPztrmJSqE_NRIm1iNJH9wKNEE.5G6ZEvvRTTnKcuDqahusz9LOc5JPV2tyoHBxb61nTjjIEPpq4u0WVONs3w~d53f8eae4ce8eb8d3957eec34cf6c4ca

Anstehende Termine für Provectus Biopharmaceuticals, Inc.

15.05.2024 Society for Investigative Dermatology Meeting

Zurückliegende Termine für Provectus Biopharmaceuticals, Inc.

05.04.2024 American Association for Cancer Research Meeting
22.02.2024 21:00 Business Update Call
06.11.2023 Society for Melanoma Research Congress - Combination PV-10 autolytic immunotherapy
06.11.2023 Society for Melanoma Research Congress - Percutaneous autolytic immunotherapy
01.11.2023 Society for Immunotherapy of Cancer Meeting
01.12.2022 Melanoma Bridge Conference
22.06.2022 22:00 Annual Genral Meeting
17.06.2022 International Society of Ocular Oncology Congress
06.06.2022 20:15 American Society of Clinical Oncology Meeting - Abstract No 9543
08.04.2022 American Association of Cancer Research Meeting - Abstract No 2720
10.03.2022 European Neuroendocrine Tumor Society Conference - Abstract No: 3455, I25
28.10.2021 Society for Melanoma Research Meeting - Cutaneous Melanoma
28.10.2021 Society for Melanoma Research Congress - Checkpoint Blockade
16.09.2021 ESMO Congress Conference - Abstract No - 4354
23.06.2021 22:00 Annual Genral Meeting
09.11.2020 Society of Immunotherapy of Cancer Meeting - Abstract Number : 585
19.09.2020 European Society for Medical Oncology Virtual Congress - Poster No -4397
19.09.2020 European Society for Medical Oncology Virtual Congress - Poster No -4281
22.06.2020 American Association for Cancer Research Virtual Meeting - Abstract number: 5393
29.05.2020 American Society of Clinical Oncology Virtual Jahreshauptversammlung - Abstract No - 1
  1. Börse
  2. Aktien
  3. A1XCTC Aktie
  4. A1XCTC Aktie
  5. Termine Provectus Biopharmaceuticals, Inc.